Stiff Person Spectrum Disorder — Research Summary
Printed from RareWays (rareways.com.au) on 11 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Understanding stiff-person syndrome: Epidemiological trends, diagnostic challenges, and treatment advances.
Riveros Daniela et al. — Journal of neuroimmunology (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41793840/
- 2.
CAR T cell therapy: Autoimmune neurological uses and neurotoxicities.
Friedman Alec R et al. — Best practice & research. Clinical rheumatology (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41934064/
- 3.
Stiff-person syndrome with concurrent Graves disease: a rare autoimmune overlap.
Rayan Melanie Natasha et al. — JCEM case reports (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41884087/
- 4.
Exteroceptive Reflex Myoclonus Triggered by Distal Nerve Stimulation in Anti-GAD65 Stiff-Person Syndrome.
Sim Jingwei et al. — Movement disorders clinical practice (25 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41878800/
- 5.
[
Dorneich Julia S et al. — Annals of clinical and translational neurology (24 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41876947/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Stiff Person Spectrum Disorder
Stiff Person Spectrum Disorder is a rare autoimmune neurological condition causing progressive muscle rigidity, painful spasms, and heightened sensitivity to stimuli. It is associated with antibodies against glutamic acid decarboxylase (GAD65) in the majority of cases. Misdiagnosis is common due to its unusual presentation. Treatment includes diazepam, baclofen, and immunotherapy.
Most Recent Research
Stiff-person syndrome spectrum disorders (SPSD) comprise a group of rare neuroimmunological conditions characterized by fluctuating muscle stiffness, painful spasms, gait disturbance, and hypersensitivity triggers. Emerging phenotypes, including posterior fossa dysfunction, highlight the heterogeneity of the spectrum. Although historically described as a "one-in-a-million" disorder, recent epidemiologic data suggest that SPSD is more common than previously recognized. Currently, consensus diagnostic criteria do not exist; however, proposed criteria emphasize key clinical findings, high titers of recognized antibodies and electrophysiology findings that help support a diagnosis. The goal of this review is to provide an overview of SPSD epidemiology with emphasis on prevalence studies, emerging diagnostic criteria and overview of the multimodal treatment approach integrating pharmacological symptomatic therapies, immunotherapy, and non-pharmacologic interventions.
Common Questions
What is Stiff Person Spectrum Disorder?
Stiff Person Spectrum Disorder is a rare autoimmune neurological condition causing progressive muscle rigidity, painful spasms, and heightened sensitivity to stimuli. It is associated with antibodies against glutamic acid decarboxylase (GAD65) in the majority of cases. Misdiagnosis is common due to its unusual presentation. Treatment includes diazepam, baclofen, and immunotherapy.
How many clinical trials are available for Stiff Person Spectrum Disorder?
RareWays currently indexes 11 clinical trials for Stiff Person Spectrum Disorder, of which 2 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Stiff Person Spectrum Disorder come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Stiff Person Spectrum Disorder.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.